Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
18 hedge funds and large institutions have $931K invested in Better Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
220% more capital inflows, than outflows
Capital inflows: $1.22M | Capital outflows: $382K
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
20% more funds holding
Funds holding: 15 → 18 (+3)
2.83% more ownership
Funds ownership: 3.4% → 6.24% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$1.07M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.4K |
| 3 |
CIAS
Capital Investment Advisory Services
Raleigh,
North Carolina
|
+$27.7K |
| 4 |
Millennium Management
New York
|
+$24.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Farallon Capital Management
San Francisco,
California
|
-$357K |
| 2 |
Renaissance Technologies
New York
|
-$14K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$10K |
| 4 |
BlackRock
New York
|
-$921 |
| 5 |
Barclays
London,
United Kingdom
|
-$251 |
BTTX Hedge Fund Activity: Q3 2023 in Review
18 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q3 2023, worth a combined $931K — down 20% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BTTX positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was MMCAP International, opening a new position worth an estimated $1.07M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $357K sold.
- 18 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q3 2023, up from 15 in Q2 2023.
- Funds reported $931K of Better Therapeutics, Inc. Common Stock stock for Q3 2023, down 20% quarter-over-quarter.
- 6 funds opened new Better Therapeutics, Inc. Common Stock positions in Q3 2023 and 3 closed out, a net change of +3 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q3 2023 was MMCAP International, an estimated $1.07M added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q3 2023 was Farallon Capital Management, an estimated $357K sold.
Based on aggregated 13F filings for Q3 2023.